Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
This office will be the central hub for all operations related to companies ethical pharmaceutical business
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Subscribe To Our Newsletter & Stay Updated